 "Lupin to market MSD's pneumococcal vaccine in India")
US-based drug maker MSD has tied up with Mumbai-based Lupin to market MSD’s 23-valent Pneumococcal Polysaccharide Vaccine in India. Under the agreement, Lupin would have a non-exclusive licence to market, promote and distribute the vaccine under a different brand name.
After the announcement, the Lupin stock touched an all-time high of Rs 904.95 in morning trade on the BSE. It closed at Rs 890.1, up 1.9 per cent.
Currently, MSD India operates in various therapeutic segments, including metabolics, cardiovascular, vaccines, critical care and oncology and accounts for a product portfolio of about 75 brands in India.
Pneumococcal disease kills more patients worldwide than any other vaccine-preventable disease. Globally, 1.6 million people die of pneumococcal disease every year — three people die every minute.
“Adults with comorbid conditions such as chronic lung disease, diabetes, chronic heart diseases, chronic liver diseases and immune compromised diseases, as well as adults aged more than 65, are at increased risk of pneumococcal disease, compared to healthy adults,” stated a Lupin release.
KG Ananthakrishnan, managing director, MSD India, said, “It is a perfect amalgamation, as MSD brings the research and scientific excellence for Pneumococcal Polysaccharide Vaccines and Lupin brings its marketing excellence and significant reach among key clinician categories to drive product access.”
After the announcement, the Lupin stock touched an all-time high of Rs 904.95 in morning trade on the BSE. It closed at Rs 890.1, up 1.9 per cent.
Currently, MSD India operates in various therapeutic segments, including metabolics, cardiovascular, vaccines, critical care and oncology and accounts for a product portfolio of about 75 brands in India.
Pneumococcal disease kills more patients worldwide than any other vaccine-preventable disease. Globally, 1.6 million people die of pneumococcal disease every year — three people die every minute.
“Adults with comorbid conditions such as chronic lung disease, diabetes, chronic heart diseases, chronic liver diseases and immune compromised diseases, as well as adults aged more than 65, are at increased risk of pneumococcal disease, compared to healthy adults,” stated a Lupin release.
KG Ananthakrishnan, managing director, MSD India, said, “It is a perfect amalgamation, as MSD brings the research and scientific excellence for Pneumococcal Polysaccharide Vaccines and Lupin brings its marketing excellence and significant reach among key clinician categories to drive product access.”